SINGAPORE, 23 September 2019 — Proteona Pte. Ltd has launched its first Proteona Oncology Challenge, co-sponsored by NovogeneAIT.
Proteona welcomes scientists and clinicians who are working the field of oncology to submit their abstracts on the use of ESCAPETM RNA-Seq single cell proteogenomic analysis services.
The winning submission will be awarded up to USD 50,000 worth of single cell analysis services from Proteona and NovogeneAIT, which will include ESCAPETM RNA-Seq single cell data acquisition and access to Proteona's AI analysis tools.
Even with the emergence of new approaches to cancer treatments such as, immunotherapy, and cell therapy, more research and development is needed to significantly improve clinical outcomes.
The challenge will be targeted at clinicians and scientists researching on utilising new technologies in single cell multi-omics analysis to address issues such as patient-to-patient variation, tumour heterogeneity, and identification of novel biomarkers that can aid in clinical decision-making.
"There are a lot of great ideas out there on how single cell multi-omics analysis can solve real clinical problems. We want to help putting them into action. By providing some additional resources, we hope to help clinical researches to get over the initial technical and financial barrier, so that they can make full use of this powerful tool to make a difference in future cancer treatment," says Dr. Andreas Schmidt, CEO of Proteona. "We will work very closely with the challenge winners and support them both on the wetlab and bioinformatics side."
Application is now open till the 1st of November 2019, full details of the grant challenge can be found at: www.proteona.com/Challenge.shtml